A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?
Phase: PHASE2 | Sponsor: Anna Rose Childress, Ph.D. | Compound: Psilocybin
- Status
- recruiting
- Institution
- Anna Rose Childress, Ph.D.
- Start date
- 2025-10-07
- End date
- 2027-10-01
- Registry ID
- NCT06786325
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.